Company Description
Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer.
Our novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations, and increases upon activation to enable selective depletion of disease-driving cells while preserving normal immune function.
By replacing broad immunosuppression with selective elimination of principal cells that drive disease, we believe our approach can do for immune-mediated diseases what precision oncology has done for cancer, transforming the treatment paradigm for patients.
To our knowledge, we are the first company to advance this SIRP-targeted precision immune cell depletion approach into clinical development and demonstrate proof-of-concept in humans.
Our lead product candidate is ipsoprubart, which is currently in a global registrational program for patients with secondary hemophagocytic lymphohistiocytosis (sHLH).
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Quehuong (Kathy) Dong, Pharm.D., M.B.A. |
Contact Details
Address: 230 E Grand Avenue, Suite S-100 South San Francisco, CA 94080 United States | |
| Phone | (888) 743-2290 |
| Website | electra-therapeutics.com |
Stock Details
| Ticker Symbol | ETRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2088082 |
| Employer ID | 83-2193635 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Quehuong (Kathy) Dong, Pharm.D., M.B.A. | President, Chief Executive Officer, Director |
| Chris Clark, C.F.A. | Chief Financial Officer |
| Kim-Hien Dao, D.O., Ph.D. | Chief Medical Officer |
| Gary S. Koe, Ph.D. | Chief Technical Officer |
| Graham Parry, Ph.D. | Chief Scientific Officer |
| Nancy Stagliano, Ph.D. | Chairperson |
| Matthew Fust, M.B.A. | Director |
| Thomas Geninatti, Ph.D. | Director |
| Carl L. Gordon, Ph.D., C.F.A. | Director |
| Beth Seidenberg, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 10, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 26, 2026 | DRS | [Cover] Draft Registration Statement |
| Oct 30, 2025 | D | Notice of Exempt Offering of Securities |